Micap plc: Commencement of clinical trials into MRSA

15-Jul-2004

Micap plc announces the commencement of a research study incorporating a Phase 1 Clinical Trial at South Manchester University Hospitals Trust into the effects of Micap(TM) encapsulated essential oils and biocide combinations against MRSA

Micap has received clearance from the Manchester Local Research Ethics Committee (LREC) to carry out a research study that will incorporate a phase 1 clinical trial of its Micap (TM) encapsulated biocide and essential oil product for the control of Methicillin-resistant Staphylococcus aureus (MRSA). In addition to the safety factors usually considered during Phase 1 trials, this study will also investigate the efficacy of the product on the patients in the trial.

This will be a randomised study involving 40 patients attending burns clinics and who have been diagnosed as having MRSA on their skin. The study will be based in the Burns Unit of Wythenshawe Hospital, part of South Manchester University Hospitals Trust under the direction of Mr. Ken Dunn, Consultant Burns and Plastic Surgeon, and will be carried out in conjunction with the Department of Biological Sciences at Manchester Metropolitan University.

In vitro studies have already demonstrated the efficacy of the product in controlling numerous strains of MRSA, including epidemic strains that are currently causing major problems in hospitals within the UK and the rest of the world. These studies involved the use of the Micap(TM) product in the decontamination of hospital environments, and showed not only increased performance but also a high level of patient acceptance of the products.

Ken Dunn said "We are looking forward to the results of the trial. MRSA continues to increase in UK hospitals and colonisation of MRSA in burns patients in particular leads to poor wound healing and long term stays in our hospitals. Currently we do not have a satisfactory solution to this problem and Micap's technology may be the answer."

On the recent progress announced by Micap, Michael Brennand, CEO, said "These developments are indicative of the widening scope of applications for our technology. It is particularly encouraging to see such rapid progress into patient trials in the area of MRSA treatment which is a huge problem in healthcare."

Hospital-acquired infections like MRSA affect around 100,000 people in England each year, costing the NHS ?1bn and causing an estimated 5,000 deaths.

https://www.bionity.com/en/news/38514/micap-plc-commencement-of-clinical-trials-into-mrsa.html